Cambiotics Helps to Reduce the Body’s Toxic Load Via the Microbiome
Laura McQuarrie — February 12, 2026 — Lifestyle
References: insider.fitt.co
99% of all humans have detectable levels of PFAS or "forever chemicals" in their bodies and Cambiotics is on a mission to reduce toxic load with a precision-formulated probiotic.
PFAS have infiltrated nearly every aspect of modern life, from non-stick cookware to packaging and water-resistant clothing, making them virtually impossible to avoid. Formulated to support the body's natural process for removing forever chemicals, Cambiotics' probiotic features specialized strains that interact with PFAS molecules in the gut so that they can be moved through the digestive system. Coming in 2026, the Precision Probiotics for PFAS Removal is designed by a combination of two natural, non-GMO probiotic strains (specifically, 46-XY1 and 46-SL1) with no antimicrobial resistance markers.
In partnership with Quest Diagnostics, Cambiotics offers a test for PFAS levels in blood.
PFAS have infiltrated nearly every aspect of modern life, from non-stick cookware to packaging and water-resistant clothing, making them virtually impossible to avoid. Formulated to support the body's natural process for removing forever chemicals, Cambiotics' probiotic features specialized strains that interact with PFAS molecules in the gut so that they can be moved through the digestive system. Coming in 2026, the Precision Probiotics for PFAS Removal is designed by a combination of two natural, non-GMO probiotic strains (specifically, 46-XY1 and 46-SL1) with no antimicrobial resistance markers.
In partnership with Quest Diagnostics, Cambiotics offers a test for PFAS levels in blood.
Trend Themes
-
Microbiome-driven Detoxification — Customized gut strains capable of binding and facilitating excretion of persistent pollutants create pathways for personalized chemical detox regimens.
-
Precision Probiotics — Engineered or selected probiotic formulas matched to specific contaminant chemistries offer a new class of non-invasive therapeutics for bioaccumulation reduction.
-
Diagnostic-linked Therapeutics — Integration of exposure biomarker testing with targeted microbial treatments enables closed-loop care models that align interventions to individual toxin burdens.
Industry Implications
-
Nutraceuticals — Formulation of evidence-backed probiotic products designed to remove environmental toxins could pivot supplements toward regulated, clinically validated offerings.
-
Clinical Diagnostics — Combining blood-level PFAS assays with companion microbiome therapies opens pathways for diagnostic-driven treatment protocols and new reimbursement models.
-
Environmental Health Services — Providers that pair community exposure assessment with microbiome-based mitigation strategies may create scalable remediation services for contaminated populations.
5.5
Score
Popularity
Activity
Freshness